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Abstract
Prodigiosin and obatoclax, members of the prodiginines family, are small molecules with anti-cancer properties that are
currently under preclinical and clinical trials. The molecular target(s) of these agents, however, is an open question.
Combining experimental and computational techniques we find that prodigiosin binds to the BH3 domain in some BCL-2
protein families, which play an important role in the apoptotic programmed cell death. In particular, our results indicate
a large affinity of prodigiosin for MCL-1, an anti-apoptotic member of the BCL-2 family. In melanoma cells, we demonstrate
that prodigiosin activates the mitochondrial apoptotic pathway by disrupting MCL-1/BAK complexes. Computer simulations
with the PELE software allow the description of the induced fit process, obtaining a detailed atomic view of the molecular
interactions. These results provide new data to understand the mechanism of action of these molecules, and assist in the
development of more specific inhibitors of anti-apoptotic BCL-2 proteins.
Citation: Hosseini A, Espona-Fiedler M, Soto-Cerrato V, Quesada R, Pe´rez-Toma´s R, et al. (2013) Molecular Interactions of Prodiginines with the BH3 Domain of
Anti-Apoptotic Bcl-2 Family Members. PLoS ONE 8(2): e57562. doi:10.1371/journal.pone.0057562
Editor: Aleksey Porollo, University of Cincinnati College of Medicine, United States of America
Received July 17, 2012; Accepted January 26, 2013; Published February 27, 2013
Copyright:  2013 Hosseini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a research grant from the Spanish government and the European Union (FIS-PI10/00338) and from the ERC-2009-Adg
25027-PELE European project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: victor.guallar@bsc.es
. These authors contributed equally to this work.
Introduction
In order to advance in molecular target therapies, it is important
to elucidate the target and the atomic detailed mechanisms of
protein-drug interactions. A wide set of experimental techniques,
such as crystallography, NMR, calorimetry, etc, together with
theoretical docking efforts aim to address this issue. Recently, we
have turned our attention in solving the molecular target and the
binding mechanism for prodigiosin (PG). PG, a bacterial metab-
olite from the prodiginine family (see Figure 1), has shown
apoptotic activity against several cancer cell types with low
cytotoxicity in non-malignant cells. The National Cancer Institute
(dtp.nci.nih.gov) tested prodigiosin against a collection of ,60
cancerous cell lines with an average half maximal inhibitory
concentration (IC50) of 2.1 mM [1]. Furthermore, recent studies
elucidated that PG triggers apoptosis by the intrinsic pathway [2],
provoking the increase in the pro-apoptotic NAG-1 protein and
the negative cell cycle regulator p21 [3], and inducing down-
regulation of the inhibitor of apoptosis survivin [4], SKP2 [5] and
RAD51 [6] proteins. Nevertheless, the direct molecular target(s) of
this agent is still an open question.
Apoptosis, the programmed cell death that controls removal of
damaged cells, is extremely well regulated by the extrinsic and
intrinsic pathways. The key regulator proteins of the intrinsic
pathway are known as the BCL-2 family, being BAX and BAK the
pro-apoptotic members responsible for the mitochondrial outer
membrane permeabilisation. Cytochrome c is then released to the
cytosol allowing the activation of procaspase-9, leading to cell
death [7]. In survival conditions, BAX and BAK are sequestered
by the anti-apoptotic family members: BCL-2, BCL-XL, MCL-1,
BCL-W, BCL-B and BCL2A1. These anti-apoptotic proteins
share four regions of high sequence similarity known as the BCL-2
Homology (BH) domain, (BH1, BH2, BH3 and BH4). When
a stress stimulus occurs, BH3-only proteins bind to the BH3
domain of anti-apoptotic BCL-2 proteins, displacing and releasing
pro-apoptotic BAK or BAX, committing the cell to death. [7,8].
BH3-mimetic molecules have emerged as promising anti-cancer
drugs since they are able to directly reverse the evasion of
apoptosis [9]. This is the case for Obatoclax (OBX), which binds
to a broad spectrum of BCL-2 family members [10–13]. To
elucidate whether PG also behaves as a BH3-mimetic drug and
how these interactions occur at the molecular level, we combined
again immunoprecipitation assays with in silico modeling [14]. We
focused on MCL-1, BCL-xL and BCL-2, three anti-apoptotic
proteins representative of selectivity patterns among BH3 domains
within the BCL-2 family that have centered most of recent studies
[15–17]. We find that PG antagonizes MCL-1 by binding to the
BH3 domain triggering BAK release. Furthermore, we obtain an
atomic detailed description of PG’s interaction in the BH3
domain. Altogether, these results show, for the first time, the
BH3 mimetic nature of PG and provide a detailed atomic view of
the molecular interactions of prodiginines (PGs) with the BH3
domain of several antiapoptotic BCL-2 proteins.
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Materials and Methods
Reagents
Prodigiosin (2-methyl-3-pentyl-6-methoxyprodigiosene) was
provided by Dr. R. J. Schultz of the National Cancer Drug
Synthesis and Chemistry Branch Chemotherapeutic Agents Re-
pository (Bethesda, MD). Obatoclax, a synthetic indol-containing
prodiginine, was prepared by acid catalyzed condensation of 2-(4-
methoxy-5-vinyl-1H-pyrrol-2-yl)-1H-indole and 2,4-dimethyl-1H-
pyrrole [18]. All stock solutions were diluted in DMSO and stored
at 220uC.
Cell Lines and Culture Conditions
Human melanoma cancer cell line SK-MEL-5 was purchased
from the American Type Culture Collection (Manassas, VA). Cells
were cultured in Dulbeccos Modified Eagles Medium (DMEM,
Biological Industries, Beit Haemek, Israel) supplemented with
10% heat-inactivated foetal bovine serum (FBS; Life Technolo-
gies, Carlsbad, CA), 100 U/ml penicillin, 100 mg/ml streptomy-
cin, and 2 mM L- glutamine, all from Biological Industries. Cells
were grown at 37uC in a 5% CO2 atmosphere.
Immunoblot Analysis
After their respective treatments, adherent and floating cells
were lysed in immunoprecipitation (IP) buffer (50 mM Tris
(pH 8.0), 60 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5% Nonidet
P-40 (IGEPAL), 10 mM sodium vanadate, 50 mM NaF, 1 mg/ml
aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin and 0.1 mM
PMSF) or lysis buffer (0.1% SDS, 1% NP-40, 0.5% sodium
deoxycholate, 50 mM NaF, 40 mM b-glycerophosphate, 200 mM
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride and
serine and cysteine protease inhibitor cocktail (Roche
11836170001)) for MCL-1 overexpression analysis. Total cell
extracts were centrifuged at 120006g for 10 min at 4uC. Protein
concentration was determined with the BCA protein assay (Pierce,
Rockford, IL) using bovine serum albumin as standard. 40 mg of
protein extracts were separated by SDS-PAGE and transferred to
Immobilon-P membranes (Millipore, Bedford, MA). They were
then incubated with primary antibodies anti-MCL-1, BCL-2,
BAK, BAX, and actin (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), anti-Caspase- 9 and PARP (Cell Signalling, Beverly,
MA) or anti-Vinculin (Sigma-Aldrich Chemical Co., St.Louis,
MO) according to the manufacturer’s instructions. Antibody
binding was detected with secondary antibodies conjugated to
peroxidase and the ECL detection kit (Amersham, Buckingham-
shire, UK).
Co-immunoprecipitation from Cells
Cell extracts (800 mg of protein) were brought to a volume of
1 ml with IP buffer and incubated with 2 mg of anti-MCL-1
antibody (Santa Cruz Biotechnology), anti-BAK (Cell Signalling
Technology) or anti-BAX antibody (Invitrogen, Carlsbad, CA)
overnight at 4uC. Immune complexes were precipitated by
incubation with protein A-coated agarose beads (Sigma-Aldrich
Chemical Co.) previously equilibrated with IP buffer, and washed
three times with 0.5 ml of IP buffer. Immunoprecipitated proteins
were loaded on a 12% SDS-PAGE gel and analyzed by
Immunoblot using anti-MCL-1, anti-BAK and anti-BAX anti-
bodies (Santa Cruz Biotechnology).
MCL-1 Overexpression and Cell Viability Evaluation
SK-MEL-5 cells were seeded in 6-well plates and allowed to
grow up to 70% confluence. Before transfection, growth media
was replaced by Optimem media without FBS (Invitrogen) and
1 mg of plasmidic DNA was transfected to cells using 20 ml of
lipofectin reagent (Invitrogen) per condition. Empty pcDNA3-
GFP vector or pTOPOMCL1 plasmid (Addgene plasmid 21605
[19], were used. After 20 h of transfection, the media was replaced
by complete media with or without 2 or 20 mM PG or OBX,
respectively. After 24 h of treatment, cells were resuspended and
100 ml of each condition were passed in triplicate to a 96-well
plate. Cell viability was determined using the methyl-thiazole-
tetrazolium (MTT) assay [20]. Briefly, 10 mM of MTT (Sigma
Chemical Co.) was added to each well for an additional 2 h. The
blue MTT formazan precipitate was dissolved in 100 ml of
isopropanol: 1N HCl (24:1). The absorbance at 570 nm was
measured on a multiwell plate reader. Cell viability was expressed
as a percentage of non-treated cells and data are shown as the
mean value 6 S.D. of two independent experiments. Statistical
analysis (ANOVA and LSD tests) was carried out with the
STATGRAPHICS Centurion XVI.I. statistical package. P,0.05
and P,0.01 were represented with * and **, respectively. To
determine transfection efficiency, immunoblot analyses were
performed to assess MCL1 protein expression levels in each
condition.
Analyses with Isolated Mitochondria
SK-MEL-5 cells were treated with PG (100 nM), OBX (10 mM)
or DMSO (vehicle) at 37uC for 24 h. Cells were lysed in ice-cold
25 mM Tris (pH 6.8), 250 mM sucrose, 1 mM EDTA, 0.05%
digitonin, 1 mM DTT, 1 mg/ml aprotinin, 1 mg/ml leupeptin,
Figure 1. The ligands used. The ligands used in this study are
shown: prodigiosin, obatoclax, ligand number 6 (a rhodanine derivative)
and ABT-737.
doi:10.1371/journal.pone.0057562.g001
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1 mg/ml pepstatin, 0.1 mM PMSF. Samples were then centri-
fuged at 130006g for 5 min at 4uC. Mitochondrial fraction (pellet)
was isolated, washed once and resuspended with lysis buffer. Total
cell lysate, mitochondrial and cytosolic fractions were analyzed by
Immunoblot using cytochrome c, porin and actin antibodies
(Santa Cruz Biotechnology).
Computational Methods
Computational docking was modeled by combining PELE
(Protein Energy Landscape Exploration) [21] with Glide [22]. To
map protein-ligand conformational changes and induced fit we
used our in house program PELE, a Monte Carlo algorithm where
new trial configurations are produced with sequential ligand (and
protein) perturbation, side chain prediction and minimization
steps. Ligand perturbation includes a ligand specific rotamer
library. Trial configurations are then filtered with a Metropolis
acceptance test, where the energy is described with an all-atom
OPLS force field with a surface generalized Born solvent model.
PELE has recently shown to provide more accurate induced fit
results than the state of the art commercial software [23], and to
reproduce the conformational sampling obtained in microsecond
molecular dynamics trajectories with two orders of magnitude
reduction in computational cost [24].
We have modeled PG and OBX binding to three different anti-
apoptotic BCL-2 members for which crystal structures and
inhibitors (as controls) are known: MCL-1, BCL-2 and BCL-xl.
MCL-1. To model MCL-1 we used the crystal structure
bound to a BH3-peptide, pdb code 2NLA [25]. For the control
simulation we used the ligand named 6, a derivative of rhodanine
that has and IC50 of 0.25 mM [26]. Additionally, OBX has been
shown to bind to MCL-1 with an IC50 of 2.9 mM. [10–13].
BCL-2. To model BCL-2 the crystal structure bound to the
43B peptide (BH3 mimic), pdb code 1YSW was used [27]. For the
control simulation we used the ligand ABT-737, with an IC50 of
0.12 mM [10,28].
BCL-xL. To model BCL-xL we used a crystal structure bound
to a known inhibitor, ABT-737, with pdb code 2YXJ [28,29]. For
Figure 2. PG is a BH3-mimetic molecule. (A and B) PG disrupts constitutive MCL-1/BAK interaction. Cell lysates were subjected to
immunoprecipitation with anti-MCL-1 or anti-BAK antibody after PG treatment at 1 mM (8 h) and 100 nM (24 h), respectively. (C) PG permeabilizes
the outer mitochondrial membrane. BAX was immunoprecipitated from PG (50, 100 and 500 nM), OBX (10 mM) or DMSO- treated cells for 24 h
and then BAK/BAX complex formation was analyzed by immunoblot with anti-BAK and anti-BAX antibodies.
doi:10.1371/journal.pone.0057562.g002
Figure 3. PG induces activation of the intrinsic apoptotic pathway. (A) PG induces cytochrome c release to the cytosol. Cytochrome c release
from SK-MEL-5 isolated mitochondria after PG and OBX treatment. Mitochondria were isolated from PG (100 nM), OBX (10 mM) or DMSO- treated cells
for 24 h. Cytochrome c release from mitochondria to cytosol was analyzed by Immunoblot using the mitochondrial marker porin as a quality control
of the isolation process. (B) Activation of caspases. Cells were treated with PG (100 nM) or OBX (10 mM) for 24 h and total cell lysates were
analyzed by immunoblot. Actin was used as loading control.
doi:10.1371/journal.pone.0057562.g003
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the control simulation we used the ligand present in the initial
crystal, ABT-737, with an IC50 of 0.06 mM [10,29].
All ligands used in this study are shown in Figure 1.
For all systems we removed the crystallographic ligands and
prepared the protein with Schrodinger’s Protein Wizard [30]. This
algorithm builds hydrogen-bonded clusters and performs 100000
Monte Carlo moves by reorienting hydroxyl and thiol groups,
water molecules, amide groups of Asn and Gln, and the imidazole
ring in His. The algorithm also predicts protonation states of His,
Asp, Glu, Lys and Arg. Each possibility is scored based on the total
number of hydrogen bonds and their quality (relative to an
idealized hydrogen bond). In particular, all Asp, Glu, Lys and Arg
kept their anionic state. Histidines 224, 252 and 277 in MCL-1,
and 117 and 183 in BCL-2 were epsilon protonated; all other
histidines kept the default delta protonation. The ligand’s atomic
charges were derived from the electrostatic potential fitting of
a single point DFT/B3LYP calculation with the 6-31G** basis set.
Ligand docking and induced fit procedure. After the
protein and ligand’s preparations, we performed a cavity search
with SiteMap [31], which confirmed the BH3 domain as the top
ranked binding cavity in the three systems. Initial rigid docking
was performed with Glide [22] using the extra precision (XP)
scoring function [32], currently viewed as the state of the art
docking software/procedure. Correlation of Glide scores with
binding affinities, however, can only be done at a qualitative level.
While score values below 28/29 indicate a good binder, a more
Figure 4. Effect of MCL-1 overexpression on cell viability. (A) MCL-1 overexpression partially blocks PGs cytotoxicity. SK-MEL-5 cells were
transfected with 1 mg of pTOPOMCL1 plasmid and, after 20 h, cells were treated with PGs (2 and 20 mM, respectively) for an addittional 24 h. Then
cell viability was assessed by the MTT assay. (B) Analysis of MCL-1 protein levels. After MCL1 overexpression and PGs treatment, MCL-1 protein
levels were analyzed by Immunoblot. Vinculin was used as a loading control.
doi:10.1371/journal.pone.0057562.g004
Table 1. Before and after induced fit docking scores.
MCL-1 BCL-xL BCL-2
Ligands PG OBX 6 PG OBX ABT PG OBX ABT
Initial Score 24.3 22.9 26.0 27.0 23.4 27.9 26.3 26.0 28.5
Final Score 28.6 28.8 28.7 27.4 28.3 213.9 27.9 28.8 29.6
RMSD 3.0 4.0 7.4 3.0 5.5 1.4 4.8 4.5 4.0
Also shown is the ligand RMSD along the induced fit process.
doi:10.1371/journal.pone.0057562.t001
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quantitative assessment requires a system specific control. Thus,
for each protein we docked an inhibitor with known (good)
binding affinities. Comparing the values predicted for these
control ligands with those obtained for PG, we could estimate
more accurately their binding strength.
Following the rigid docking we performed 8 independent PELE
trajectories, each including 600 iterations (24 hours), of induced
fitted adjustment. We then clustered the trajectory in 5 groups,
based on the ligand’s heavy atom root mean square deviation
(RMSD), and selected the median in each group. For each
representative cluster we re-docked all ligands with Glide. Thus,
for each system and ligand we have two XP score values: an initial
one biased to the crystal structure and a final score after the
induced fit (the largest score from the 5 clusters), which aims to
adapt the protein to each specific ligand.
Results
PG Disrupts MCL-1/BAK Complex in Melanoma Cells
BCL-2 family member MCL-1 binds to and regulates BAK
within the mitochondrial outer membrane [33] and the BH3
mimetic molecule OBX has been reported to inhibit this
constitutive interaction [34]. To examine whether PG could also
alter this binding, MCL-1/BAK complex was co-immunoprecipi-
tated from PG, OBX or DMSO- treated SK-MEL-5 cells. In
DMSO-treated cells, MCL-1 was co-immunoprecipitated with
BAK using MCL-1 antibody, indicating that these proteins
heterodimerize in basal conditions. Alternatively, treatment with
PG or OBX resulted in a complete release of BAK from MCL-1,
showing the BH3 mimetic nature of PGs (Figure 2A). As MCL-1
levels were downregulated by 1 mM PG, lower doses were used to
corroborate these results. Similarly, BAK immunoprecipitation
resulted in the appearance of MCL-1/BAK complex in non-
treated cells, whilst this binding disappeared in treated cells and no
protein level modifications were observed (Figure 2B). Finally,
since BAK and BAX heterodimerize when they are released from
their anti-apoptotic proteins MCL-1 and BCL-2 (in order to form
pores in the mitochondrial membrane), the formation of this
complex was analyzed in treated cells. As observed in Figure 2C,
after 24 h of treatment, PG as well as OBX induced BAK/BAX
complex formation, indicating mitochondrial membrane permea-
bilization.
Mitochondrial Apoptosis is Triggered after PGs
Treatment
At the same time that MCL-1/BAK complex was disrupted by
PGs treatment and the mitochondrial membrane pore was
formed, we observed cytochrome c release from the mitochondria
to the cytosol (Figure 3A). This protein binds to Apaf-1 and
caspase-9 to form the apoptosome and this complex facilitates
caspase-9 activation by proteolysis. In Figure 3B we can observe
cleaved caspase-9 appearance after PGs treatment, indicating its
activation. Moreover, we also observe cleavage of the caspase
Figure 5. Induced fit docked structures. Top panels (A): final induce fit structures in MCL-1 (left) BCL-xl (center) and BCL-2 (right). Bottom panles
(B): detailed view of the molecular interactions of PG, OBX and 6 with MCL-1.
doi:10.1371/journal.pone.0057562.g005
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substrate called PARP, corroborating caspases activation. Alto-
gether these results demonstrate the activation of the intrinsic
apoptotic pathway after PGs treatment.
MCL-1 Overexpression Partially Abrogates PGs Induced
Cell Death
To elucidate whether MCL-1 was involved in the cytotoxic
effect triggered by PGs, MCL-1 was overexpressed in SK-MEL-5
cells. After 20 h from transfection, PGs treatment was added
during 24 h and cell viability was analyzed by MTT assay
(Figure 4). PGs-induced cytotoxic effect was significantly blocked
by overexpressing MCL-1. These results might suggest that PGs
are not able to disrupt all the MCL-1/BAK complexes when
MCL-1 is overexpressed, preventing some BAK protein to form
mitochondrial membrane pores, though being lower the apoptotic
effect. Figure 4 B shows MCL-1 protein levels at basal or
overexpressing conditions after PGs treatment.
Molecular Docking
Table 1 summarizes the docking results for MCL-1, BCL-xL,
and BCL-2. Besides from PG and OBX, for each anti-apoptotic
target we have docked a control ligand known to be a good binder.
For each ligand and target we show the initial docking score,
biased towards the initial (crystal) structure, and the final score as
a results of the induced fit (after PELE simulation). For MCL-1 the
initial docking was performed after removing the BH3 peptide
from the crystal structure. Thus, we expect a significant RMSD
change and an improvement in the docking score along the
induced fit process. Clearly for all ligands we observe a large
RMSD, ranging from 3 to 7, and a significant increase in the
score. Interestingly, similar scores (,29) are obtained for the
control, ligand 6, and for the two prodiginines under study, OBX
and PG.
For BCL-xL the initial crystal structure used to model the target
already has the control ligand ABT-737 bound to it. Thus, as
expected, we observe the lowest induced fit RMSD for this ligand,
1.4 A˚. Additionally, we find good initial and (very good) final
scores for ABT-737 a potent inhibitor of BCL-xL from Abbott
Laboratories with an IC50 of 0.06 mM [10]. For OBX we observe
5.5 A˚ RMSD change along the PELE simulation, together with
a large improvement of its binding score. For PG, we observe
a lower final score and a medium induced fit, pointing to
micromolar rather than nanomolar activity.
In BCL-2 our model was derived from a peptide (43B) bound
crystallographic structure. Accordingly, we observe again signifi-
cant induced fit RMSD changes and improvements in the scores.
For ABT-737 we observe good initial scores and the lower RMSD,
possibly as a result of its large size and excellent BH3 helix mimetic
properties. As expected from its IC50 of 0.12 mM [10], the final
score is 29.6. OBX is again the second best scorer followed by
PG.
Figure 5 shows the induced fit structures obtained after
modeling with PELE. The left panel in Figure 5A compares the
final structures for OBX, PG and 6 in the BH3 binding domain of
MCL-1. The center and right panels show the final structures
obtained for OBX and PG in BCL-xL and BCL-2. For simplicity,
we superimpose the final position for each ligand into a consensus
ribbon representation. In all three proteins, PG and OBX use
slightly different regions of the BH3 domain and present different
protein-ligand interactions. Figure 5B shows the protein-ligand
interactions for PG, OBX and 6 with MCL-1. All three ligands
bind to the hydrophobic core defined by Val253, Val249, Ala227
and Leu267. PG forms a hydrogen bond with Thr266, OBX
makes a hydrogen bond with Met231 and ligand 6 makes
hydrogen bonds with Asn260 and Arg263. Despite sharing
a similar molecular skeleton, PG and OBX present important
differences in the hydrogen bond network. As seen in Figure 1,
a hydrogen bond acceptor ring in PG turns into a hydrogen bond
Figure 6. MCL-1 contact map with PG. (A) Crystal structure of the
mNoxaB BH3 peptide bound to MCL-1. In cyan we show Gly82, the 11
helix residue located in the h3 position. Leu267 in blue, Thr266 in red
and His224 in green. from MCL-1 are also shown. (B) Pharmacophore
analysis of the binding interactions. Residues within 3 A˚ from the ligand
have been included in the anlysis.
doi:10.1371/journal.pone.0057562.g006
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donor in OBX, explaining the differences in the binding modes. In
supporting information we provide a pharmacophore analysis
(Supplementary Figure S1) and the atomic coordinates (in pdb
format) for the docked structures shown in Figure 5A, the best
scoring structures for each ligand and protein.
Discussion
The proapoptotic agent prodigiosin has shown an average IC50
value of 2.1 mM when tested against a collection of,60 cancerous
cell lines [1]. Thus, it seems a good candidate as a base drug to
carry on further development. For this, it is necessary to elucidate
its target(s) and obtain an atomic detailed description of its binding
mechanism. In a previous study we analyzed the interactions of
PG and OBX with several kinases, demonstrating that the
mammalian target of rapamycin (mTOR) is a molecular target
of both PGs in melanoma [14]. Moreover, these results also
showed that inhibition of mTOR was accompanied by the
activation of both cell death mechanisms, autophagy and
apoptosis. Here we show how PG, as indicated previously for
OBX [10], binds to the BH3 domain of the anti-apoptotic BCL-2
family, synergizing the proapoptotic effects induced by mTOR
inhibition. In particular, in melanoma cells, we demonstrate that
PG disrupts the interaction between MCL-1 and BAK, allowing
the formation of BAK/BAX complex and the subsequent
cytochrome c release to the cytosol, which mediates the
mitochondrial apoptosis activation. Moreover, MCL-1 has been
identified as a molecular target directly involved in PGs induced
cell death, since its overexpression is able to decrease PGs
cytotoxicity.
In order to characterize the protein-drug complex, we used
recent advances in protein-ligand recognition software. It is clear
from the results that the induced fit process is essential in order to
get good binding affinities. Rigid docking into the crystals, for
example, would fail to recognize ligand 6 as a nanomolar binder in
MCL-1. Furthermore, the induced fit simulations allow comparing
the ABT-737 scores with the experimental IC50 in BCL-xL and
BCL-2. Overall, the results with the two prodiginines and the
three BCL-2 family members indicate good protein-ligand
interactions when compared to control ligands. In MCL-1, in
particular, PG scores are similar to the control ligand, suggesting
an IC50 in the hundreds of nanomolar range.
PG, OBX and ligand 6 bind in a specific region of the MCL-1
BH3 domain, defined by a hydrophobic core including Val253,
Val249, Ala227 and Leu267. This region corresponds closely to
the h1–h3 position of the BH3 peptides. Figure 6A shows the
interaction of a BH3 helix peptide with MCL-1. Peptide residue
11, located at the h3 position of the helix (G82 in the crystal
structure, shown in cyan), is a conserved small residue in contact
with the hydrophobic core, which has been shown to be important
for ligand binding [35,36]. Additional studies by Chen et al. [15]
and Day et al. [37] have also underlined the importance of
positions h1 and h3 for binding to MCL-1 and BCL-xL.
Computational studies also pointed to this hydrophobic core in
the MCL-1 ligand recognition [26,38]. Interestingly, in BCL-xL,
the two prodiginines have more distant binding modes, centered in
the h1–h2 region, in agreement with the larger degree of flexibility
observed in this end of the helix for BCL-xL [35,36].
Figure 6B shows a pharmacophore analysis for the PG/MCL-1
binding interactions (the other ligand and proteins are shown in
supporting information). Clearly, the combination of the hydro-
phobic interactions (in green) together with the hydrogen bond to
Thr266 play a key role in PG’s binding. Stacking to His224 is also
underlined in the pharmacophore analysis [15]. To further
analyze the role of Thr266, we have modeled a single mutation
T266A in the active site of MCl-1. The final score, associated with
a 4.2A˚ RMSD, is reduced to 26.3 (instead of a 28.6 for the wild
type), indicating the importance of this residue for binding.
Obviously, confirmation of these binding modes simulations and
residue analysis will require future directed mutagenesis.
The identification of PG as a new BH3 mimetic molecule,
together with previous results demonstrating the potential of PG as
an inhibitor for both mTOR complexes [14], evidences the
potential of PG as a chemotherapeutic agent. In fact, emergent
molecular therapies are focused on molecules that are able to
target multiple proteins involved in cell survival. Molecules such as
PP242 (ATP mimetic inhibitor) [39] or ABT-263 (analog of ABT-
737) [40] have shown similar successful results as OBX in clinical
trials [11,34]. Nevertheless, combinational strategies are still
necessary to improve the effect of these molecules. Based on
previous results which markedly enhanced OBX-mediated cell
death [12,13], we might consider combining PG with the ER stress
inducers such as tunicamycin [41], cisplatin [42] or sorafenib
[43,44] which markedly enhanced apoptotic cell death.
Altogether, our results demonstrate, for the first time, that
MCL-1 is a molecular target of PG involved in its cytotoxic effect
and that this is due to the capacity of PG to displace activating
BH3 proteins from the pocket of MCL-1 triggering BAK
oligomerization and the subsequent cytochrome c release-mediat-
ed apoptosis.
Supporting Information
The coordinates (in pdb format) and pharmacophore analyses
are provided for the best scoring structures for each ligand and
protein.
Supporting Information
Figure S1 Pharmacophore analysis. Pharmacophore anal-
ysis for the binding interactions of all residues with all proteins.
Residues within 3 A˚ from the ligand have been included in the
anlysis.
(PDF)
File S1 The coordinates (in pdb format) are provided
for the best scoring structures for each ligand and
protein.
(PDB)
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